Navigation Links
Patient Survival Rises When Drugs Suppress Hepatitis C in Blood: Study
Date:12/25/2012

TUESDAY, Dec. 25 (HealthDay News) -- Patients with hepatitis C who have no detectable virus in their blood for six months after treatment are less likely to die than those who don't have this "sustained viral response" after treatment, a new study finds.

"Sustained viral response was associated with prolonged overall survival," wrote a Dutch team led by Dr. Adriaan van der Meer, of Erasmus MC University Medical Center, Rotterdam. "The risk of all-cause mortality was almost fourfold lower in [these] patients" compared to patients whose viral load was not suppressed for six months or more, they said.

In the article, published in the Dec. 26 issue of the Journal of the American Medical Association, the researchers noted that "chronic hepatitis C virus infection is a major cause of cirrhosis, hepatocellular carcinoma [liver cancer], and end-stage liver disease," and the incidence of these types of virus-linked illnesses "is expected to increase in upcoming years."

The researchers cited a prior study that estimated that about one-quarter of the 3.5 million Americans with chronic hepatitis C infection will develop cirrhosis, and that number could rise to 45 percent by 2030.

In the new study, van der Meer's team looked at 530 hepatitis C patients with advanced liver fibrosis, which is scarring that occurs in response to liver damage. The Canadian and European patients began interferon-based treatment between 1990 and 2003, and were followed for a median of more than eight years.

Among the patients, 192 (36 percent) achieved sustained viral response, according to a journal news release. However, only 13 of the patients with a sustained response died, compared to 100 of those patients who did not maintain viral suppression, the researchers found.

Of the deaths in the 100 patients without sustained viral response, the cause was liver-related in 70 patients, non-liver-related in 15 patients, and unknown in the other 15 patients.

Van der Meer's team determined that the 10-year, all-cause death rate was about 9 percent among patients with sustained viral response and 26 percent among those without this response -- a significant difference.

Further analysis showed that sustained viral response was associated with a reduced risk of all-cause death, liver-related death, and liver transplantation.

The 10-year rate of liver-related death or liver transplantation was about 2 percent in patients with a sustained viral response but more than 27 percent in those without it, the researchers reported. The 10-year rate of liver cancer was about 5 percent in patients with good responses and nearly 22 percent for those who did not respond to treatment as well.

Finally, the 10-year rate of liver failure was about 2 percent in patients with a sustained viral response and almost 30 percent in those without it, the investigators found.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about hepatitis C.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, Dec. 25, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Higher-spending hospitals have fewer deaths for emergency patients
2. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
3. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
4. Study finds doctors have exaggerated fears when starting patients on insulin
5. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
6. Predictors identified for rehospitalization among post-acute stroke patients
7. Pulse pressure elevation could presage cerebrovascular disease in Alzheimers patients
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Heart failure patients with diabetes may benefit from higher glucose levels
10. Gastro Woes Often Strike Rheumatoid Arthritis Patients
11. Short Walks May Ease Fatigue in Pancreatic Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patient Survival Rises When Drugs Suppress Hepatitis C in Blood: Study
(Date:7/21/2017)... ... July 21, 2017 , ... "As a doctor of lung medicine ... catheters available on the market," said an inventor from Center Valley, Pa. "My idea ... the patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen Miller ... to communities in the greater Birmingham area, is joining the Chris Hammond Youth ... people in the region. , The Chris Hammond Youth Foundation maintains athletic facilities ...
(Date:7/21/2017)... ... July 21, 2017 , ... Bernard R. Bach, Jr., MD, orthopaedic ... American Orthopaedic Society of Sports Medicine (AOSSM) , received the 2017 Robert E. ... Meeting in Toronto, Canada. This prestigious award is given annually to honor those who ...
(Date:7/21/2017)... MO (PRWEB) , ... July 21, 2017 , ... “Kids ... knowing how to tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive ... Time-In Toolkit, which launches on Kickstarter on Monday, July 21st. , The kit ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians ... on the rise, say researchers presenting their work at the American Orthopaedic ... “The combination of evaluating the patterns of change in concussion symptom presentation, diagnostic ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... its senior management team will host a conference call and webcast ... The dial-in number to access the call is U.S./ ... passcode is 45397076. Please dial in 10 minutes prior to the ... replay of the call will be available from August 8, 2017 ...
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
Breaking Medicine Technology: